You have free access to this content

Cancer

Cover image for Vol. 117 Issue 15

1 August 2011

Volume 117, Issue 15

Pages 3287–3535

  1. CancerScope

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Review Articles
    5. Original Articles
    6. Correspondence
    7. Erratum
    1. You have free access to this content
    2. You have free access to this content
  2. Editorials

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Review Articles
    5. Original Articles
    6. Correspondence
    7. Erratum
    1. You have free access to this content
      Technology impacting on biology : Spine radiosurgery (pages 3290–3292)

      Yoshiya Yamada and Mark H. Bilsky

      Version of Record online: 11 FEB 2011 | DOI: 10.1002/cncr.25921

      Improvements in technology using image-guided techniques have allowed the accurate delivery of high-dose radiation that is characteristic of stereotactic body radiotherapy. Image-guided high-dose radiation is a new treatment paradigm that provides tumor ablative therapy.

  3. Review Articles

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Review Articles
    5. Original Articles
    6. Correspondence
    7. Erratum
    1. You have free access to this content
      FLT3 inhibitors in the treatment of acute myeloid leukemia : The start of an era? (pages 3293–3304)

      Naveen Pemmaraju, Hagop Kantarjian, Farhad Ravandi and Jorge Cortes

      Version of Record online: 11 FEB 2011 | DOI: 10.1002/cncr.25908

      • original image

      Agents that target Fms-like tyrosine kinase 3 (FLT3) currently are in development for the treatment of patients with acute myeloid leukemia (AML) and offer a potential paradigm change in the current standard AML treatment. The authors of this report reviewed the prognostic significance of genetic alterations observed in AML with a focus on the therapeutic implications of targeting FLT3.

  4. Original Articles

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Review Articles
    5. Original Articles
    6. Correspondence
    7. Erratum
    1. Disease Site

      Breast Disease
      You have free access to this content
      Trends in the use of implantable accelerated partial breast irradiation therapy for early stage breast cancer in the United States (pages 3305–3310)

      Andrea M. Abbott, Elizabeth B. Habermann and Todd M. Tuttle

      Version of Record online: 1 FEB 2011 | DOI: 10.1002/cncr.25927

      • original image
      • original image

      The incidence of implantable accelerated partial breast irradiation (IAPBI) increased from 0.4% in 2000 to 6.8% in 2007 (an increase of approximately 1600%). IAPBI use is more common in older, white women with stage I breast cancer.

    2. You have free access to this content
      Using breast cancer quality indicators in a vulnerable population (pages 3311–3321)

      Formosa Chen, Melissa Puig, Irina Yermilov, Jennifer Malin, Eric C. Schneider, Arnold M. Epstein, Katherine L. Kahn, Patricia A. Ganz and Melinda Maggard Gibbons

      Version of Record online: 24 JAN 2011 | DOI: 10.1002/cncr.25915

      • original image
      • original image

      Adherence rates to 31 breast cancer quality indicators were compared with previously published 5-city cohort results. Findings show that it is possible to deliver breast cancer care to vulnerable patients comparable in quality to the care received by the broader population.

    3. You have free access to this content
      Cost-effectiveness of chemoprevention of breast cancer using tamoxifen in a postmenopausal US population (pages 3322–3331)

      Joyce Noah-Vanhoucke, Linda E. Green, Tuan A. Dinh, Peter Alperin and Robert A. Smith

      Version of Record online: 14 MAR 2011 | DOI: 10.1002/cncr.25926

      • original image
      • original image
      • original image

      Tamoxifen chemoprophylaxis for breast cancer was cost-saving relative to no treatment for postmenopausal women aged <55 years who had a predicted 5-year breast cancer risk ≥1.66%.

    4. Endocrine Disease
      You have free access to this content
      Neuroendocrine tumors of midgut and hindgut origin: Tumor-node-metastasis classification determines clinical outcome (pages 3332–3341)

      Henning Jann, Stephanie Roll, Anne Couvelard, Olivia Hentic, Marianne Pavel, Jacqueline Müller-Nordhorn, Martin Koch, Christoph Röcken, Guido Rindi, Philippe Ruszniewski, Bertram Wiedenmann and Ulrich-Frank Pape

      Version of Record online: 18 JAN 2011 | DOI: 10.1002/cncr.25855

      • original image
      • original image
      • original image
      • original image

      This study demonstrated the significant prognostic value of tumor-node-metastasis (TNM)-based staging and Ki67-based grading of neuroendocrine tumors of midgut and/or hindgut origin. TNM staging and Ki67 grading allows appropriate stratification for therapeutic decision making.

    5. Gastrointestinal Disease
      You have free access to this content
      Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal (pages 3342–3351)

      Jose G. Bazan, Wendy Hara, Annie Hsu, Pamela A. Kunz, James Ford, George A. Fisher, Mark L. Welton, Andrew Shelton, Daniel S. Kapp, Albert C. Koong, Karyn A. Goodman and Daniel T. Chang

      Version of Record online: 1 FEB 2011 | DOI: 10.1002/cncr.25901

      • original image
      • original image
      • original image

      Patients with squamous cell carcinoma of the anal canal were compared by treatment, either conventional radiotherapy (CRT) or intensity-modulated radiotherapy (IMRT). In patients treated with IMRT, the results were improved toxicity profile, reduced frequency of treatment breaks, shorter duration of overall therapy, and excellent locoregional control and overall survival.

    6. You have free access to this content
      Effectiveness of a patient and practice-level colorectal cancer screening intervention in health plan members : The CHOICE trial (pages 3352–3362)

      Michael Pignone, Andrea Winquist, Laura A. Schild, Carmen Lewis, Tracy Scott, Jonathan Hawley, Barbara K. Rimer and Karen Glanz

      Version of Record online: 11 FEB 2011 | DOI: 10.1002/cncr.25924

      • original image
      • original image

      Colorectal cancer (CRC) screening reduces CRC incidence and mortality but is underused. An intervention that combined a patient-directed decision aid and practice-directed academic detailing had a modest but statistically nonsignificant overall effect on colon cancer screening rates.

    7. Gynecologic Oncology
      You have free access to this content
      Identification of a gene-expression signature for predicting lymph node metastasis in patients with early stage cervical carcinoma (pages 3363–3373)

      Long Huang, Min Zheng, Qing-Min Zhou, Mei-Ying Zhang, Wei-Hua Jia, Jing-Ping Yun and Hui-Yun Wang

      Version of Record online: 11 FEB 2011 | DOI: 10.1002/cncr.25870

      • original image
      • original image
      • original image

      The authors investigated a new approach with an 11-gene signature for predicting pelvic lymph node metastasis (PLNM) that may help clinicians with planning therapies. The results also provided novel clues for developing new targeted therapy for patients with cervical carcinoma who have PLNM.

    8. Head and Neck Disease
      You have free access to this content
      A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck : A trial of the eastern cooperative oncology group (E1303) (pages 3374–3382)

      Athanassios Argiris, Musie Ghebremichael, Barbara Burtness, Rita S. Axelrod, Ronald C. Deconti and Arlene A. Forastiere

      Version of Record online: 18 JAN 2011 | DOI: 10.1002/cncr.25852

      • original image

      Bortezomib, an inhibitor of the 26S proteasome, was well tolerated as a single agent and resulted in disease stabilization in a high percentage of patients with incurable adenoid cystic carcinoma of the head and neck but produced no objective responses. The addition of doxorubicin to bortezomib at the time of progression was also well tolerated, resulted in 1 partial response, and may warrant further investigation in this disease.

    9. Hepatobiliary Disease
      You have free access to this content
      Aromatase (CYP19) promoter gene polymorphism and risk of nonviral hepatitis-related hepatocellular carcinoma (pages 3383–3392)

      Woon-Puay Koh, Jian-Min Yuan, Renwei Wang, Sugantha Govindarajan, Rowena Oppenheimer, Zhen Quan Zhang, Mimi C. Yu and Sue Ann Ingles

      Version of Record online: 11 FEB 2011 | DOI: 10.1002/cncr.25939

      • original image

      This is the first report of an association between polymorphism in the exon I.6 promoter of the CYP19 gene and risk of human hepatocellular carcinoma. It provides epidemiologic evidence for the role of hepatic aromatization of androgen into estrogen in the development of nonviral hepatitis-related hepatocellular carcinoma.

    10. You have free access to this content
      A novel serum carbohydrate marker on mucin 5AC : Values for diagnostic and prognostic indicators for cholangiocarcinoma (pages 3393–3403)

      Atit Silsirivanit, Norie Araki, Chaisiri Wongkham, Chawalit Pairojkul, Yoshiki Narimatsu, Kazuhiko Kuwahara, Hisashi Narimatsu, Sopit Wongkham and Nobuo Sakaguchi

      Version of Record online: 1 FEB 2011 | DOI: 10.1002/cncr.25912

      • original image
      • original image
      • original image
      • original image
      • original image

      An S121 monoclonal antibody that recognizes a novel glycan epitope was established. The S121-reactive antigen was detected strongly in cholangiocarcinoma tissues and in sera from patients with 87.63% sensitivity and 89.58% specificity and was related to poor patient outcome.

    11. Lung Disease
      You have free access to this content
      A novel exon 15-deleted, splicing variant of Slit2 shows potential for growth inhibition in addition to invasion inhibition in lung cancer (pages 3404–3415)

      Yu-Ying Lin, Chun-Hung Yang, Gwo-Tarng Sheu, Chi-Ying F. Huang, Yu-Chung Wu, Shu-Ming Chuang, Ming-Ji Fann, Han Chang, Huei Lee and Jinghua Tsai Chang

      Version of Record online: 24 JAN 2011 | DOI: 10.1002/cncr.25890

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      A novel exon 15-Deleted Slit2, Slit2-ΔE15, inhibited both cell growth and invasion of CL1-5 lung cancer cells. However, in the presence of exon 15, Slit2-WT only exhibited invasion inhibition capacity.

    12. You have free access to this content
      Immunohistochemical subtyping of nonsmall cell lung cancer not otherwise specified in fine-needle aspiration cytology : A retrospective study of 103 cases with surgical correlation (pages 3416–3423)

      Luisella Righi, Paolo Graziano, Alessandro Fornari, Giulio Rossi, Mattia Barbareschi, Alberto Cavazza, Giuseppe Pelosi, Giorgio V. Scagliotti and Mauro Papotti

      Version of Record online: 18 JAN 2011 | DOI: 10.1002/cncr.25830

      • original image
      • original image
      • original image

      Different treatment strategies are effective according to tumor histotypes. A 4-antibody panel approach may refine lung cancer classification in fine-needle aspiration cytology, remarkably reducing the nonsmall cell lung cancer “not otherwise specified” category.

    13. You have free access to this content
      Performance of a standardized bronchoalveolar lavage protocol in a comprehensive cancer center : A prospective 2-year study (pages 3424–3433)

      Fotis Sampsonas, Dimitrios P. Kontoyiannis, Burton F. Dickey and Scott E. Evans

      Version of Record online: 18 JAN 2011 | DOI: 10.1002/cncr.25905

      • original image
      • original image
      • original image

      The current results indicated that microbiologic diagnoses are critical to pneumonia treatment, but lack of standardized bronchoalveolar lavage protocols limits interpretation of clinical trial results. In this study, the authors investigated the performance of a technically standardized BAL procedure in terms of both lavage mechanics and diagnosis.

    14. Neuro-Oncology
      You have free access to this content
      Hyperbaric oxygen treatment improved neurophysiologic performance in brain tumor patients after neurosurgery and radiotherapy : A preliminary report (pages 3434–3444)

      Nico A. M. Schellart, Dik Reits, Adrian J. van der Kleij and Lukas J. A. Stalpers

      Version of Record online: 1 FEB 2011 | DOI: 10.1002/cncr.25874

      • original image
      • original image
      • original image
      • original image

      Cognitive performance often is impaired permanently in long-term brain tumor survivors after neurosurgery and radiotherapy. From the outcomes of 2 cognitive tests, a questionnaire, and electroencephalograph responses to a visual odd-ball stimulus, the authors tentatively concluded that hyperbaric oxygen treatment improves neurophysiologic performance in long-term brain tumor survivors.

    15. Sarcoma
      You have free access to this content
      ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma (pages 3445–3456)

      Antoine Italiano, Armelle Laurand, Audrey Laroche, Paolo Casali, Roberta Sanfilippo, Axel Le Cesne, Ian Judson, Jean-Yves Blay, Isabelle Ray-Coquard, Binh Bui, Jean-Michel Coindre, Antonio Nieto, Juan-Carlos Tercero, Jose Jimeno, Jacques Robert and Philippe Pourquier

      Version of Record online: 1 FEB 2011 | DOI: 10.1002/cncr.25925

      • original image
      • original image
      • original image
      • original image
      • original image

      The authors investigated biomarkers that indicated potential clinical benefit from trabectedin, a drug that has been approved in Europe for the treatment of patients with advanced soft-tissue sarcoma (STS). The results suggested that the status of the genes excision repair cross-complementation group 5 (ERCC5), ERCC1, and breast cancer 1 (BRCA1) represents a potential DNA repair signature that could be used for the prediction of clinical response to trabectedin in patients with STS.

    16. You have free access to this content
      Effect of the histone deacetylase inhibitor SNDX-275 on Fas signaling in osteosarcoma cells and the feasibility of its topical application for the treatment of osteosarcoma lung metastases (pages 3457–3467)

      Nadezhda V. Koshkina, Krithi Rao-Bindal and Eugenie S. Kleinerman

      Version of Record online: 1 FEB 2011 | DOI: 10.1002/cncr.25884

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      The authors investigated the topical application of a histone deacetylase inhibitor as an aerosol for the treatment of osteosarcoma lung metastasis in vivo. The results indicated that there is a potential role for the Fas death receptor mechanism in response to this treatment.

    17. You have free access to this content
      A phase 2 study of temsirolimus (CCI-779) in patients with soft tissue sarcomas : A study of the Mayo phase 2 consortium (P2C) (pages 3468–3475)

      Scott Okuno, Howard Bailey, Michelle R. Mahoney, Douglas Adkins, William Maples, Tom Fitch, David Ettinger, Charles Erlichman and Jann N. Sarkaria

      Version of Record online: 1 FEB 2011 | DOI: 10.1002/cncr.25928

      • original image
      • original image

      Temsirolimus has limited activity in soft tissue sarcoma. The response rate per Response Evaluation Criteria in Solid Tumors was 5%, and median progression-free survival was 2 months.

    18. Discipline

      Disparities Research
      You have free access to this content
      Racial variation in willingness to trade financial resources for life-prolonging cancer treatment (pages 3476–3484)

      Michelle Y. Martin, Maria Pisu, Robert A. Oster, Julie M. Urmie, Deborah Schrag, Haiden A. Huskamp, Jeannette Lee, Catarina I. Kiefe and Mona N. Fouad

      Version of Record online: 26 APR 2011 | DOI: 10.1002/cncr.25839

      Blacks are more willing to exhaust personal financial resources for life-prolonging cancer treatment. Understanding variations in cancer treatment and outcomes across demographic groups requires conceptual models that reflect the complexity of treatment preferences and the delivery of cancer care.

    19. Pediatric Oncology
      You have free access to this content
      Dapsone-induced methemoglobinemia : A dose-related occurrence? (pages 3485–3492)

      Adam J. Esbenshade, Richard H. Ho, Ayumi Shintani, Zhiguo Zhao, Lesley-Ann Smith and Debra L. Friedman

      Version of Record online: 18 JAN 2011 | DOI: 10.1002/cncr.25904

      Dapsone is an effective drug used for Pneumocystis jiroveci prophylaxis, but is associated with increased risk of methemoglobinemia, thus limiting its use. Higher dosing of dapsone increases the risk of methemoglobinemia.

    20. You have free access to this content
      Rhabdomyosarcoma in infants younger than 1 year : A report from the Children's Oncology Group (pages 3493–3501)

      Suman Malempati, David A. Rodeberg, Sarah S. Donaldson, Elizabeth R. Lyden, James R. Anderson, Douglas S. Hawkins and Carola A. S. Arndt

      Version of Record online: 24 JAN 2011 | DOI: 10.1002/cncr.25887

      • original image
      • original image
      • original image

      Clinical characteristics, outcomes, patterns of failure, and treatment received were analyzed for infants with rhabdomyosarcoma (RMS) who were treated on Intergroup Rhabdomyosarcoma Study protocols. Infants with RMS appeared to have worse outcomes than older patients, in part because of high rates of local failure.

    21. Radiation Oncology
      You have free access to this content
      Adjuvant radiotherapy for completely resected stage 2 thymoma (pages 3502–3508)

      Abigail T. Berman, Leslie Litzky, Virginia Livolsi, Sunil Singhal, John C. Kucharczuk, Joel D. Cooper, Joseph R. Friedberg, Tracey L. Evans, James P. Stevenson, James M. Metz, Stephen M. Hahn and Ramesh Rengan

      Version of Record online: 1 FEB 2011 | DOI: 10.1002/cncr.25851

      Recurrence rates are low following resection of stage 2 thymoma either with or without adjuvant radiotherapy. Adjuvant radiotherapy did not significantly decrease the local relapse rate in our study, but it was well-tolerated without significant toxicity.

    22. You have free access to this content
      Prospective evaluation of spinal reirradiation by using stereotactic body radiation therapy : The University of Texas MD Anderson Cancer Center Experience (pages 3509–3516)

      Amit K. Garg, Xin-Shelley Wang, Almon S. Shiu, Pamela Allen, James Yang, Mary Frances McAleer, Syed Azeem, Laurence D. Rhines and Eric L. Chang

      Version of Record online: 11 FEB 2011 | DOI: 10.1002/cncr.25918

      • original image
      • original image
      • original image
      • original image

      Stereotactic body radiotherapy is an effective treatment option in select patients with progressive spinal metastases despite previous radiotherapy. Treatment recommendations should be tailored based on location of disease and proximity to the spinal cord.

    23. Translational Research
      You have free access to this content
      RECK in osteosarcoma : A novel role in tumour vasculature and inhibition of tumorigenesis in an orthotopic model (pages 3517–3528)

      Jonathan C. M. Clark, Toru Akiyama, David M. Thomas, Agatha Labrinidis, Andreas Evdokiou, Stuart J. Galloway, Han-Soo Kim, Crispin R. Dass and Peter F. M. Choong

      Version of Record online: 1 FEB 2011 | DOI: 10.1002/cncr.25757

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      RECK was absent from human osteosarcoma cells but preserved in intratumor vessels. Overexpression of RECK in osteosarcoma cells inhibited tumor growth and metastasis in an orthotopic mouse model.

  5. Correspondence

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Review Articles
    5. Original Articles
    6. Correspondence
    7. Erratum
    1. You have free access to this content
    2. You have free access to this content
    3. You have free access to this content
    4. You have free access to this content
    5. You have free access to this content
    6. You have free access to this content
    7. You have free access to this content
    8. You have free access to this content
      Reply to balancing the harms and benefits of early detection of prostate cancer (page 3534)

      Pim J. van Leeuwen and David Connolly

      Version of Record online: 11 FEB 2011 | DOI: 10.1002/cncr.25920

  6. Erratum

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Review Articles
    5. Original Articles
    6. Correspondence
    7. Erratum
    1. You have free access to this content
      Erratum (page 3535)

      Version of Record online: 10 JAN 2011 | DOI: 10.1002/cncr.25916

SEARCH

SEARCH BY CITATION